2026Q1FALSE0001425450--12-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURiso4217:GBPkids:subsidiaryiso4217:BRLkids:daykids:segmentkids:supplier00014254502026-01-012026-03-3100014254502026-04-2900014254502026-03-3100014254502025-12-310001425450us-gaap:NonrelatedPartyMember2026-03-310001425450us-gaap:NonrelatedPartyMember2025-12-310001425450us-gaap:RelatedPartyMember2026-03-310001425450us-gaap:RelatedPartyMember2025-12-3100014254502025-01-012025-03-310001425450us-gaap:CommonStockMember2025-12-310001425450us-gaap:AdditionalPaidInCapitalMember2025-12-310001425450us-gaap:RetainedEarningsMember2025-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001425450us-gaap:RetainedEarningsMember2026-01-012026-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001425450us-gaap:CommonStockMember2026-01-012026-03-310001425450us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001425450us-gaap:CommonStockMember2026-03-310001425450us-gaap:AdditionalPaidInCapitalMember2026-03-310001425450us-gaap:RetainedEarningsMember2026-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001425450us-gaap:CommonStockMember2024-12-310001425450us-gaap:AdditionalPaidInCapitalMember2024-12-310001425450us-gaap:RetainedEarningsMember2024-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-3100014254502024-12-310001425450us-gaap:RetainedEarningsMember2025-01-012025-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001425450us-gaap:CommonStockMember2025-01-012025-03-310001425450us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001425450us-gaap:CommonStockMember2025-03-310001425450us-gaap:AdditionalPaidInCapitalMember2025-03-310001425450us-gaap:RetainedEarningsMember2025-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100014254502025-03-310001425450kids:LOCAcquisitionMember2026-01-012026-03-310001425450kids:LOCAcquisitionMember2025-01-012025-03-310001425450kids:BostonBraceInternationalInc.Member2026-01-012026-03-310001425450kids:BostonBraceInternationalInc.Member2025-01-012025-03-310001425450kids:MedtechConceptsLLCMember2023-05-012023-05-010001425450kids:MedtechConceptsLLCMemberus-gaap:CommonStockMember2023-05-012023-05-010001425450kids:MedtechConceptsLLCMemberus-gaap:CommonStockMember2023-05-010001425450kids:MedtechConceptsLLCMember2023-05-010001425450kids:MedtechConceptsLLCMember2024-01-012024-12-310001425450kids:MedtechConceptsLLCMemberus-gaap:StockCompensationPlanMember2024-01-012024-12-310001425450kids:MedtechMember2025-05-092025-05-090001425450kids:MedtechMemberkids:SellerOneMember2025-05-092025-05-090001425450kids:MedtechConceptsLLCMember2025-01-012025-12-310001425450kids:MedtechConceptsLLCMemberus-gaap:CommonStockMember2025-01-012025-12-310001425450kids:MedtechConceptsLLCMemberus-gaap:StockCompensationPlanMember2025-01-012025-12-310001425450kids:DomesticClinicsMemberkids:BostonBraceInternationalInc.Member2025-01-012025-03-310001425450kids:BostonBraceInternationalInc.Memberkids:DomesticClinicsMember2025-01-012025-03-310001425450kids:DomesticClinicsMemberkids:PromissoryNoteMaturingDecember2025Memberkids:BostonBraceInternationalInc.Member2025-12-310001425450kids:A5.00GBPPromissoryNoteMemberkids:BostonBraceInternationalInc.Member2025-07-110001425450kids:BostonBraceInternationalInc.Memberkids:OrthoticAndProstheticDevicesMember2025-07-112025-07-110001425450kids:OPEUB.V.Memberkids:OrthoticAndProstheticDevicesMember2025-07-012025-07-310001425450kids:A4.00EuroDebtInstrumentMemberkids:OPEUB.V.Memberus-gaap:SecuredDebtMember2025-07-310001425450kids:A4.00EuroDebtInstrumentMemberkids:OPEUB.V.Member2025-07-310001425450us-gaap:CustomerRelationshipsMemberkids:OrthoticAndProstheticDevicesMemberkids:OPEUB.V.Member2025-07-012025-07-310001425450kids:OrthoPediatricsEULimitedMemberkids:OrthoticAndProstheticDevicesMember2025-08-012025-08-310001425450kids:A5.00GBPPromissoryNoteMemberkids:OrthoPediatricsEULimitedMemberus-gaap:SecuredDebtMember2025-08-310001425450us-gaap:CustomerRelationshipsMemberkids:DomesticClinicsMemberkids:OrthoPediatricsEULimitedMember2025-08-012025-08-310001425450kids:OrthoPediatricsEULimitedMemberkids:DomesticClinicsMember2025-08-012025-08-310001425450kids:TheLondonOrthoticConsultancyLtdLOCMemberkids:OrthoPediatricsEULimitedMember2026-02-012026-02-010001425450kids:TheLondonOrthoticConsultancyLtdLOCMemberkids:A4.5GBPPromissoryNoteMemberkids:OrthoPediatricsEULimitedMember2026-02-010001425450kids:TheLondonOrthoticConsultancyLtdLOCMemberkids:OrthoPediatricsEULimitedMember2026-02-010001425450kids:TheLondonOrthoticConsultancyLtdLOCMemberus-gaap:CustomerRelationshipsMemberkids:OrthoPediatricsEULimitedMember2026-02-012026-02-010001425450kids:OrthoPediatricsEULimitedMember2026-02-012026-02-010001425450kids:TheLondonOrthoticConsultancyLtdLOCMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberkids:OrthoPediatricsEULimitedMember2026-02-012026-02-010001425450kids:TheLondonOrthoticConsultancyLtdLOCMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberkids:OrthoPediatricsEULimitedMember2026-02-012026-02-010001425450kids:LocalDistributorMemberkids:OrthopediatricsDoBrasilLtdaMember2025-11-252025-11-250001425450kids:LocalDistributorMemberkids:OrthopediatricsDoBrasilLtdaMember2025-11-250001425450kids:LocalDistributorMemberkids:OrthopediatricsDoBrasilLtdaMember2025-12-310001425450kids:LocalDistributorMemberkids:OrthopediatricsDoBrasilLtdaMember2026-03-310001425450kids:LocalDistributorMemberus-gaap:CustomerRelationshipsMemberkids:OrthopediatricsDoBrasilLtdaMember2025-11-250001425450kids:LocalDistributorMemberus-gaap:NoncompeteAgreementsMemberkids:OrthopediatricsDoBrasilLtdaMember2025-11-250001425450us-gaap:PatentsMember2026-03-310001425450kids:IntellectualPropertyAndCapitalizedSoftwareMember2026-03-310001425450us-gaap:CustomerRelationshipsMember2026-03-310001425450us-gaap:LicensingAgreementsMember2026-03-310001425450us-gaap:PatentsMember2025-12-310001425450kids:IntellectualPropertyAndCapitalizedSoftwareMember2025-12-310001425450us-gaap:CustomerRelationshipsMember2025-12-310001425450us-gaap:LicensingAgreementsMember2025-12-310001425450us-gaap:TrademarksMember2026-03-310001425450us-gaap:TrademarksMember2025-12-310001425450us-gaap:TrademarksMemberkids:ApiFixLtdMember2025-01-012025-12-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001425450us-gaap:CorporateDebtSecuritiesMember2026-03-310001425450us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001425450us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001425450us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001425450us-gaap:USTreasurySecuritiesMember2026-03-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001425450us-gaap:AssetBackedSecuritiesMember2026-03-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001425450kids:ExchangeTradeMutualFundsMember2026-03-310001425450kids:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel1Member2026-03-310001425450kids:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel2Member2026-03-310001425450kids:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Member2026-03-310001425450kids:ContingentConsiderationLiabilityMember2026-03-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001425450us-gaap:CorporateDebtSecuritiesMember2025-12-310001425450us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001425450us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001425450us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001425450us-gaap:USTreasurySecuritiesMember2025-12-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001425450us-gaap:AssetBackedSecuritiesMember2025-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001425450kids:ExchangeTradeMutualFundsMember2025-12-310001425450us-gaap:RevolvingCreditFacilityMemberkids:TermLoanMember2026-03-310001425450us-gaap:RevolvingCreditFacilityMemberkids:TermLoanMember2025-12-310001425450us-gaap:ConvertibleNotesPayableMember2026-03-310001425450us-gaap:ConvertibleNotesPayableMember2025-12-310001425450us-gaap:MortgagesMember2026-03-310001425450us-gaap:MortgagesMember2025-12-310001425450kids:AcquisitionNotesMemberus-gaap:NotesPayableOtherPayablesMember2026-03-310001425450kids:AcquisitionNotesMemberus-gaap:NotesPayableOtherPayablesMember2025-12-310001425450kids:TermLoanAgreementMember2024-08-050001425450kids:DelayedDrawTermLoanFacilityMember2024-08-050001425450kids:DelayedDrawTermLoanFacilityMember2025-06-272025-06-270001425450kids:TermLoanAgreementMembersrt:MinimumMember2024-08-052024-08-050001425450kids:PeriodOneMemberkids:TermLoanAgreementMemberus-gaap:ScenarioPlanMember2024-08-050001425450kids:PeriodTwoMemberkids:TermLoanAgreementMemberus-gaap:ScenarioPlanMember2024-08-050001425450kids:TermLoanAgreementMemberkids:PeriodThreeMember2024-08-050001425450kids:TermLoanAgreementMemberkids:PeriodFourMember2024-08-050001425450kids:TermLoanAgreementFirstAmendmentMember2026-03-310001425450kids:TermLoanAgreementFirstAmendmentMembersrt:MinimumMember2026-03-312026-03-310001425450kids:TermLoanAgreementFirstAmendmentMember2024-08-050001425450kids:TermLoanAgreementFirstAmendmentMember2026-03-312026-03-310001425450kids:A4.75ConvertibleSeniorNotesMemberus-gaap:ScenarioPlanMember2024-08-050001425450kids:A4.75ConvertibleSeniorNotesMemberus-gaap:ScenarioPlanMember2024-08-052024-08-050001425450us-gaap:MortgagesMember2026-01-012026-03-310001425450kids:AcquisitionPromissoryNotesMemberus-gaap:NotesPayableOtherPayablesMember2026-03-310001425450kids:AcquisitionPromissoryNotesMemberus-gaap:NotesPayableOtherPayablesMember2025-12-310001425450kids:AcquisitionNotesMembersrt:MinimumMemberus-gaap:NotesPayableOtherPayablesMember2026-03-310001425450kids:AcquisitionNotesMembersrt:MaximumMemberus-gaap:NotesPayableOtherPayablesMember2026-03-310001425450us-gaap:RestrictedStockMember2025-12-310001425450us-gaap:RestrictedStockMember2025-01-012025-12-310001425450us-gaap:RestrictedStockUnitsRSUMember2025-12-310001425450us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-12-310001425450us-gaap:RestrictedStockMember2026-01-012026-03-310001425450us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001425450us-gaap:RestrictedStockMember2026-03-310001425450us-gaap:RestrictedStockUnitsRSUMember2026-03-310001425450us-gaap:RestrictedStockMember2025-01-012025-03-310001425450kids:TermLoanAgreementMember2024-08-020001425450kids:TermLoanAgreementMember2024-12-310001425450country:US2026-01-012026-03-310001425450country:US2025-01-012025-03-310001425450us-gaap:NonUsMember2026-01-012026-03-310001425450us-gaap:NonUsMember2025-01-012025-03-310001425450kids:TraumaAndDeformityMember2026-01-012026-03-310001425450kids:TraumaAndDeformityMember2025-01-012025-03-310001425450kids:SpineMember2026-01-012026-03-310001425450kids:SpineMember2025-01-012025-03-310001425450kids:SportsMedicineAndOtherMember2026-01-012026-03-310001425450kids:SportsMedicineAndOtherMember2025-01-012025-03-310001425450srt:AffiliatedEntityMember2026-01-012026-03-310001425450srt:AffiliatedEntityMemberkids:StructureMedicalLLCMemberkids:SupplierMember2026-01-012026-03-310001425450srt:AffiliatedEntityMemberkids:StructureMedicalLLCMemberkids:SupplierMember2025-01-012025-03-310001425450kids:VilexAndOrthexMember2019-06-012019-06-300001425450kids:SquadronCapitalLLCMemberkids:TeamNoteBMembersrt:AffiliatedEntityMember2019-12-312019-12-310001425450us-gaap:LicensingAgreementsMemberkids:FireflyTechnologyMember2021-07-202021-07-200001425450kids:FireflyTechnologyMember2026-01-012026-03-310001425450kids:FireflyTechnologyMember2025-12-310001425450kids:FireflyTechnologyMember2026-03-310001425450srt:MinimumMember2026-01-012026-03-310001425450srt:MaximumMember2026-01-012026-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-38242

OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)


Delaware			26-1761833
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification Number)


2850 Frontier Drive Warsaw, IN 46582			(574) 268-6379
(Address of principal executive offices, including zip code)			(Registrant’s telephone number, including area code)

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00025 par value per share

KIDS

Nasdaq Global Market

________________________________________________________________________________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 29, 2026, the registrant had 25,684,994 outstanding shares of common stock, $0.00025 par value per share.

OrthoPediatrics Corp.

Form 10-Q

For the Quarterly Period Ended March 31, 2026

TABLE OF CONTENTS


		Page No.
Note Regarding Forward-Looking Statements		3

PART I. FINANCIAL INFORMATION
Item 1	Financial Statements (unaudited)	4
	Condensed Consolidated Balance Sheets - March 31, 202 6 and December 31, 20 2 5	4
	Condensed Consolidated Statements of Operations - Three Months Ended March 31, 202 6 and 202 5	5
	Condensed Consolidated Statements of Comprehensive Loss - Three Months Ended March 31, 202 6 and 202 5	6
	Condensed Consolidated Statements of Stockholders' Equity - Three Months Ended March 31, 202 6 and 20 25	7
	Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 202 6 and 202 5	9
	Notes to Condensed Consolidated Financial Statements	10
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4	Controls and Procedures	32

PART II. OTHER INFORMATION
Item 1	Legal Proceedings	33
Item 1A	Risk Factors	33
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 3	Defaults Upon Senior Securities	33
Item 4	Mine Safety Disclosures	33
Item 5	Other Information	33
Item 6	Exhibits	34
Exhibit Index		35
Signatures		37

NOTE REGARDING FORWARD-LOOKING STATEMENTS

All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. You can often identify forward-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "target," "ongoing," "plan," "potential," "predict," "project," "should," "will" or "would," or the negative of these terms or other terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to:

•our ability to achieve or sustain profitability in the future;

•our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations;

•our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively;

•our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability;

•our ability to comply with extensive government regulation and oversight both in the United States and abroad;

•our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and

•our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others.

We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2026 and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ORTHOPEDIATRICS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In Thousands, Except Share Data)


	March 31, 2026		December 31, 2025
ASSETS
Current assets:
Cash	$	12,193	$	19,556
Restricted cash	2,052		2,064
Short-term investments	36,616		41,295
Accounts receivable - trade, net of allowances of $1,615 and $1,145, respectively	54,430		53,838
Inventories, net	134,021		133,790
Prepaid expenses and other current assets	6,554		5,876
Total current assets	245,866		256,419

Property and equipment, net	48,554		49,555
Other assets:
Amortizable intangible assets, net	63,802		64,802
Goodwill	115,173		109,269
Other intangible assets	12,914		12,909
Other non-current assets	15,881		15,676
Total other assets	207,770		202,656

Total assets	$	502,190	$	508,630

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade	$	19,701	$	18,786
Accrued compensation and benefits	12,768		13,693
Current portion of long-term debt with affiliate	172		170
Current portion of acquisition installment payable	2,758		2,194
Other current liabilities	11,784		11,354
Total current liabilities	47,183		46,197
Long-term liabilities:
Long-term term loan	48,312		48,189
Long-term convertible note	48,644		48,486
Long-term debt with affiliate, net of current portion	240		283
Other long-term debt, net of current portion	3,191		2,862
Acquisition installment payable, net of current portion	2,961		2,898
Deferred income taxes	3,355		3,582
Other long-term liabilities	9,592		9,537
Total long-term liabilities	116,295		115,837

Total liabilities	163,478		162,034

Stockholders' equity:
Common stock, $0.00025 par value; 50,000,000 shares authorized; 25,604,900 shares and 25,093,792 shares issued as of March 31, 2026 and December 31, 2025, respectively	6		6
Additional paid-in capital	626,009		622,325
Accumulated deficit	(285,899)		(275,212)
Accumulated other comprehensive loss	(1,404)		(523)
Total stockholders' equity	338,712		346,596
Total liabilities and stockholders' equity	$	502,190	$	508,630

ORTHOPEDIATRICS CORP 10-Q